Proliferating endothelial cell-specific expression of IGF-I receptor ribozyme inhibits retinal neovascularization

Gene Therapy

Volumn 13, Issue 9, 2006, Pages 752-760

  Shaw, L C ^a   Pan, H ^a   Afzal, A ^a   Calzi, S L ^a   Spoerri, P E ^a   Sullivan, S M ^b   Grant, M B ^a  

^a UNIVERSITY OF FLORIDA   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

Endothelial; IGF I; Proliferating; Promoter; Retinopathy; Ribozyme

Indexed keywords

CELL CYCLE PROTEIN 6; PLASMID DNA; RIBOZYME; SOMATOMEDIN C RECEPTOR;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CELL CULTURE; CELL PROLIFERATION; CHIMERA; CONSENSUS SEQUENCE; CONTROLLED STUDY; DRUG SAFETY; ENDOTHELIUM CELL; EXPRESSION VECTOR; FEASIBILITY STUDY; FEMALE; FIBROBLAST; HISTOPATHOLOGY; HUMAN; HUMAN CELL; HUMAN TISSUE; IN VIVO STUDY; MOUSE; NONHUMAN; NONVIRAL GENE DELIVERY SYSTEM; NONVIRAL GENE THERAPY; PRIORITY JOURNAL; PROLIFERATIVE RETINOPATHY; PROMOTER REGION; PROTEIN EXPRESSION; REPORTER GENE; RETINA NEOVASCULARIZATION;

ANIMALS; CELL PROLIFERATION; CELLS, CULTURED; ENDOTHELIAL CELLS; GENE EXPRESSION; GENE THERAPY; GENETIC ENGINEERING; HUMANS; LASER COAGULATION; LUCIFERASES; MICE; MICE, INBRED C57BL; MODELS, ANIMAL; PROMOTER REGIONS (GENETICS); RECEPTOR, IGF TYPE 1; RETINA; RETINAL NEOVASCULARIZATION; RNA, CATALYTIC; TRANSFECTION;

ANIMALIA;

EID: 33645999993     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/sj.gt.3302718     Document Type: Article

References (56)

1. Walker JL, Zhang L, Zhou J, Woolkalis MJ, Menke AS. Role for alpha 6 integrin during lens development: Evidence for signaling through IGF-1R and ERK. Dev Dyn 2002; 223: 273-284.
2. Rosenthal R, Wohlleben H, Malek G, Schlichting L, Thieme H, Bowes Rickman C et al. Insulin-like growth factor-1 contributes to neovascularization in age-related macular degeneration. Biochem Biophys Res Commun 2004; 323: 1203-1208.
3. Zygar CA, Colbert S, Yang D, Fernald RD. IGF-1 produced by cone photoreceptors regulates rod progenitor proliferation in the teleost retina. Brain Res Dev Brain Res 2005; 154: 91-100.
4. Li F, Cao W, Steinberg RH, LaVail MM. Basic FGF-induced down-regulation of IGF-I mRNA in cultured rat Muller cells. Exp Eye Res 1999; 68: 19-27.
5. Smith LE, Shen W, Perruzzi C, Soker S, Kinose F, Xu X et al. Regulation of vascular endothelial growth factor-dependent retinal neovascularization by insulin-like growth factor-1 receptor. Nat Med 1999; 5: 1390-1395.
6. Hellstrom A, Carlsson B, Niklasson A, Segnestam K, Boguszewski M, de Lacerda L et al. IGF-I is critical for normal vascularization of the human retina. J Clin Endocrinol Metab 2002; 87: 3413-3416.
7. Merimee TJ, Zapf J, Froesch ER. Insulin-like growth factors: Studies in diabetics with and without retinopathy. N Engl J Med 1983; 309: 527-530.
8. Grant MB, Russell B, Fitzgerald C, Merimee TJ. Insulin-like growth factors in vitreous: Studies in control and diabetic subjects with neovascularization. Diabetes 1986; 35: 416-420.
9. Dills DG, Moss SE, Klein R, Klein BE. Association of elevated IGF-I levels with increased retinopathy in late-onset diabetes. Diabetes 1991; 40: 1725-1730.
10. Hyer SL, Sharp PS, Brooks RA, Burrin JM, Kohner EM. A two-year follow-up study of serum insulinlike growth factor-I in diabetics with retinopathy. Metabolism 1989; 38: 586-589.
11. Chantelau E, Eggert H, Seppel T, Schonau E, Althaus C. Elevation of serum IGF-1 precedes proliferative diabetic retinopathy in Mauriac's syndrome. Br J Ophthalmol 1997; 81: 169-170.
12. Grant MB, Ellis EA, Caballero S. The role of insulin-like growth factor-I in proliferative diabetic retinopathy: A modulator of free radical derived oxidant generation. In: Shigeta Y, King GL (eds). Recent Advances in Endothelial Cell Dysfunction in Diabetes. Churchill Livingstone: Osaka, Japan, 1994, pp 265-280.
13. Meyer-Schwickerath R, Pfeiffer A, Blum WF, Freyberger H, Klein M, Losche C et al. Vitreous levels of the insulin-like growth factors I and II, and the insulin-like growth factor binding proteins 2 and 3, increase in neovascular eye disease. Studies in nondiabetic and diabetic subjects. J Clin Invest 1993; 92: 2620-2625.
14. Grant MB, Mames RN, Fitzgerald C, Ellis EA, Caballero S, Chegini N et al. Insulin-like growth factor I as an angiogenic agent. In vivo and in vitro studies. Ann NY Acad Sci 1993; 692: 230-242.
15. Shaw LC, Afzal A, Lewin AS, Timmers AM, Spoerri PE, Grant MB. Decreased expression of the insulin-like growth factor 1 receptor by ribozyme cleavage. Invest Ophthalmol Vis Sci 2003; 44: 4105-4113.
16. Hellstrom A, Engstrom E, Hard AL, Albertsson-Wikland K, Carlsson B, Niklasson A et al. Postnatal serum insulin-like growth factor I deficiency is associated with retinopathy of prematurity and other complications of premature birth. Pediatrics 2003; 112: 1016-1020.
17. Szymanski P, Anwer K, Sullivan S. Prolliferating endothelium specific gene expression. J Gene Med 2006 (in press).
18. Anwer K, Kao G, Proctor B, Rolland A, Sullivan S. Optimization of cationic lipid/DNA complexes for systemic gene transfer to tumor lesions. J Drug Target 2000; 8: 125-135.
19. Anwer K, Meaney C, Kao G, Hussain N, Shelvin R, Earls RM et al. Cationic lipid-based delivery system for systemic cancer gene therapy. Cancer Gene Ther 2000; 7: 1156-1164.
20. Rhee J, Hoff PM. Angiogenesis inhibitors in the treatment of cancer. Expert Opin Pharmacother 2005; 6: 1701-1711.
21. Wakelee HA, Schiller JH. Targeting angiogenesis with vascular endothelial growth factor receptor small-molecule inhibitors: Novel agents with potential in lung cancer. Clin Lung Cancer 2005; 7 (Suppl 1): S31-S38.
22. Adamis AP, Miller JW, Bernal MT, DJ DA, Folkman J, Yeo TK et al. Increased vascular endothelial growth factor levels in the vitreous of eyes with proliferative diabetic retinopathy. Am J Ophthalmol 1994; 118: 445-450.
23. Simo R, Lecube A, Segura RM, Garcia Arumi J, Hernandez C. Free insulin growth factor-I and vascular endothelial growth factor in the vitreous fluid of patients with proliferative diabetic retinopathy. Am J Ophthalmol 2002; 134: 376-382.
24. Freyberger H, Brocker M, Yakut H, Hammer J, Effert R, Schifferdecker E et al. Increased levels of platelet-derived growth factor in vitreous fluid of patients with proliferative diabetic retinopathy. Exp Clin Endocrinol Diabetes 2000; 108: 106-109.
25. Tombran-Tink J, Chader GG, Johnson LV. PEDF: A pigment epithelium-derived factor with potent neuronal differentiative activity. Exp Eye Res 1991; 53: 411-414.
26. Kommonen B, Dawson WW, Parmer R. Pigment epithelial function in canine retina. Am J Vet Res 1991; 52: 1341-1344.
27. Mori M, Ghyselinck NB, Chambon P, Mark M. Systematic immunolocalization of retinoid receptors in developing and adult mouse eyes. Invest Ophthalmol Vis Sci 2001; 42: 1312-1318.
28. Mori K, Gehlbach P, Ando A, Dyer G, Lipinsky E, Chaudhry AG et al. Retina-specific expression of PDGF-B versus PDGF-A: Vascular versus nonvascular proliferative retinopathy. Invest Ophthalmol Vis Sci 2002; 43: 2001-2006.
29. Gehlbach P, Demetriades AM, Yamamoto S, Deering T, Duh EJ, Yang HS et al. Periocular injection of an adenoviral vector encoding pigment epithelium-derived factor inhibits choroidal neovascularization. Gene Therapy 2003; 10: 637-646.
30. Rasmussen H, Chu KW, Campochiaro F, Gehlbach PL, Haller JA, Handa JT et al. Clinical protocol. An open-label, phase I, single administration, dose-escalation study of ADGVPEDF.11D (ADPEDF) in neovascular age-related macular degeneration (AMD). Hum Gene Ther 2001; 12: 2029-2032.
31. Krzystolik MG, Afshari MA, Adamis AP, Gaudreault J, Gragoudas ES, Michaud NA et al. Prevention of experimental choroidal neovascularization with intravitreal anti-vascular endothelial growth factor antibody fragment. Arch Ophthalmol 2002; 120: 338-346.
32. Hofmann F, Garcia-Echeverria C. Blocking the insulin-like growth factor-I receptor as a strategy for targeting cancer. Drug Discov Today 2005; 10: 1041-1047.
33. Wang Y, Sun Y. Insulin-like growth factor receptor-1 as an anti-cancer target: Blocking transformation and inducing apoptosis. Curr Cancer Drug Targets 2002; 2: 191-207.
34. Baserga R. The contradictions of the insulin-like growth factor 1 receptor. Oncogene 2000; 19: 5574-5581.
35. Baserga R. The IGF-I receptor in cancer research. Exp Cell Res 1999; 253: 1-6.
36. Arteaga CL, Osborne CK. Growth inhibition of human breast cancer cells in vitro with an antibody against the type I somatomedin receptor. Cancer Res 1989; 49: 6237-6241.
37. Khalili K, Del Valle L, Wang JY, Darbinian N, Lassak A, Safak M et al. T-antigen of human polyomavirus JC cooperates with IGF-IR signaling system in cerebellar tumors of the childhood-medulloblastomas. Anticancer Res 2003; 23: 2035-2041.
38. Min Y, Adachi Y, Yamamoto H, Ito H, Itoh F, Lee CT et al. Genetic blockade of the insulin-like growth factor-I receptor: A promising strategy for human pancreatic cancer. Cancer Res 2003; 63: 6432-6441.
39. Furstenberger G, Morant R, Bolliger B, Senn HJ. Serum levels of IGF-1 and IGFBP-3 during adjuvant chemotherapy for primary breast cancer. Breast 2003; 12 (Suppl 1): S31.
40. Maloney EK, McLaughlin JL, Dagdigian NE, Garrett LM, Connors KM, Zhou XM et al. An anti-insulin-like growth factor I receptor antibody that is a potent inhibitor of cancer cell proliferation. Cancer Res 2003; 63: 5073-5083.
41. Wu JD, Odman A, Higgins LM, Haugk K, Vessella R, Ludwig DL et al. In vivo effects of the human type I insulin-like growth factor receptor antibody A12 on androgen-dependent and androgen-independent xenograft human prostate tumors. Clin Cancer Res 2005; 11: 3065-3074.
42. Cohen BD, Baker DA, Soderstrom C, Tkalcevic G, Rossi AM, Miller PE et al. Combination therapy enhances the inhibition of tumor growth with the fully human anti-type 1 insulin-like growth factor receptor monoclonal antibody CP-751,871. Clin Cancer Res 2005; 11: 2063-2073.
43. 33P-ATP plate assay formats. J Exp Ther Oncol 2004; 4: 111-119.
44. Ludwig DL, Witte L, Hicklin DJ, Prewett M, Bassi R, Burtrum D et al. Conservation of receptor antagonist anti-tumor activity by epidermal growth factor receptor antibody expressed in transgenic corn seed. Hum Antibodies 2004; 13: 81-90.
45. Li W, Favelyukis S, Yang J, Zeng Y, Yu J, Gangjee A et al. Inhibition of insulin-like growth factor I receptor autophosphorylation by novel 6-5 ring-fused compounds. Biochem Pharmacol 2004; 68: 145-154.
46. Warshamana-Greene GS, Litz J, Buchdunger E, Hofmann F, Garcia-Echeverria C, Krystal GW. The insulin-like growth factor-I (IGF-I) receptor kinase inhibitor NVP-ADW742, in combination with STI571, delineates a spectrum of dependence of small cell lung cancer on IGF-I and stem cell factor signaling. Mol Cancer Ther 2004; 3: 527-535.
47. Byron SA, Yee D. Potential therapeutic strategies to interrupt insulin-like growth factor signaling in breast cancer. Semin Oncol 2003; 30: 125-132.
48. Vasilcanu D, Girnita A, Girnita L, Vasilcanu R, Axelson M, Larsson O. The cyclolignan PPP induces activation loop-specific inhibition of tyrosine phosphorylation of the insulin-like growth factor-1 receptor. Link to the phosphatidyl inositol-3 kinase/Akt apoptotic pathway. Oncogene 2004; 23: 7854-7862.
49. Ye JJ, Liang SJ, Guo N, Li SL, Wu AM, Giannini S et al. Combined effects of tamoxifen and a chimeric humanized single chain antibody against the type I IGF receptor on breast tumor growth in vivo. Horm Metab Res 2003; 35: 836-842.
50. Pollak MN, Schernhammer ES, Hankinson SE. Insulin-like growth factors and neoplasia. Nat Rev Cancer 2004; 4: 505-518.
51. Zhang H, Yee D. The therapeutic potential of agents targeting the type I insulin-like growth factor receptor. Expert Opin Investig Drugs 2004; 13: 1569-1577.
52. Smith LE, Kopchick JJ, Chen W, Knapp J, Kinose F, Daley D et al. Essential role of growth hormone in ischemia-induced retinal neovascularization. Science 1997; 276: 1706-1709.
53. Grant MG, Guay C. Plasminogen activator production by human retinal endothelial cells of nondiabetic and diabetic origin. Invest Ophthalmol Vis Sci 1991; 32: 53-64.
54. Ohki EC, Tilkins ML, Ciccarone VC, Price PJ. Improving the transfection efficiency of post-mitotic neurons. J Neurosci Methods 2001; 112: 95-99.
55. Smith LE, Wesolowski E, McLellan A, Kostyk SK, D'Amato R, Sullivan R et al. Oxygen-induced retinopathy in the mouse. Invest Ophthalmol Vis Sci 1994; 35: 101-111.
56. Grant MB, May WS, Caballero S, Brown GA, Guthrie SM, Mames RN et al. Adult hematopoietic stem cells provide functional hemangioblast activity during retinal neovascularization. Nat Med 2002; 8: 607-612.